Results of First Clinical Study of Low-Cost Retinal OCT Published
We’ve known since Lumedica’s founding that the low-cost OCT would be an effective and efficient alternative to the currently expensive Optical Coherence Tomography systems currently available for screening eye diseases. Now, Lumedica’s founder and Chief Science Officer, Dr. Adam Wax, has documented the results of a jointly-conducted clinical study between Duke and UNC that compared the OQ LabScope OCT system to a standard Heidelberg OCT system that is already on the market.
The conclusion: “The images captured with the low-cost OCT were of adequate resolution and allowed for clinical diagnostics. It offers comparable performance as a retinal screening tool at a fraction of the cost of current commercial systems.”
Dr. Wax was quoted in a statement released by Duke University, “Once you have lost vision, it’s very difficult to get it back, so the key to preventing blindness is early detection,” said Adam Wax, professor of biomedical engineering at Duke. “Our goal is to make OCT drastically less expensive so more clinics can afford the devices, especially in global health settings.”
News of this OCT cost breakthrough has been picked up by many outlets: